These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 27959485)
1. Unquantified Benefits and the Problem of Regulation Under Uncertainty. Masur JS; Posner EA Cornell Law Rev; 2016 Nov; 102(1):87-137. PubMed ID: 27959485 [No Abstract] [Full Text] [Related]
2. GAO sounds off on chemical regulation. Black H Environ Health Perspect; 2005 Dec; 113(12):A828-30. PubMed ID: 16330340 [No Abstract] [Full Text] [Related]
4. Status and plans for implementation of NRC regulatory authority for certain naturally occurring and accelerator-produced radioactive material. Mauer A J Nucl Med Technol; 2007 Jun; 35(2):112-3. PubMed ID: 17537736 [No Abstract] [Full Text] [Related]
5. Bioanalytical method validation: notable points in the 2009 draft EMA Guideline and differences with the 2001 FDA Guidance. Smith G Bioanalysis; 2010 May; 2(5):929-35. PubMed ID: 21083222 [No Abstract] [Full Text] [Related]
6. Regulatory Impact Analysis: a new tool for better regulation at ANVISA. Alves FN; Peci A Rev Saude Publica; 2011 Aug; 45(4):802-5. PubMed ID: 21779641 [TBL] [Abstract][Full Text] [Related]
7. [Price of medications: the actual system must be seen again]. Mayencourt J Rev Med Suisse; 2016 Mar; 12(508):479. PubMed ID: 27089613 [No Abstract] [Full Text] [Related]
8. The crisis in evaluation of health care technology. Ney RT; Anderson C Natl J (Wash); 1979 Sep; 11(36):1507-9. PubMed ID: 10308997 [No Abstract] [Full Text] [Related]
9. Verdict in French blood trial shames science. Butler D Nature; 1992 Oct; 359(6398):764. PubMed ID: 1436044 [No Abstract] [Full Text] [Related]
10. MPs back change in law to tighten rules on strikes. Nurs Stand; 2015 Sep; 30(4):8. PubMed ID: 26394938 [No Abstract] [Full Text] [Related]
11. US Patent Office strategic plan may penalize biotechs. Robertson D Nat Biotechnol; 2003 Apr; 21(4):345-6. PubMed ID: 12665807 [No Abstract] [Full Text] [Related]
12. Context, existing frameworks, and practicality: moving forward with synthetic biology. Carter SR Hastings Cent Rep; 2014; 44(6 Spec no.):S46-8. PubMed ID: 25418707 [No Abstract] [Full Text] [Related]
13. Price-based vs. quantity-based environmental regulation under Knightian uncertainty: an info-gap robust satisficing perspective. Stranlund JK; Ben-Haim Y J Environ Manage; 2008 May; 87(3):443-9. PubMed ID: 17363135 [TBL] [Abstract][Full Text] [Related]
14. DBS: a UK (MHRA) regulatory perspective. Beharry M Bioanalysis; 2010 Aug; 2(8):1363-4. PubMed ID: 21083336 [No Abstract] [Full Text] [Related]
15. Does vivisection pass the utiliatrian test? Kaufman SR Public Aff Q; 1995 Apr; 9(2):127-39. PubMed ID: 11653293 [No Abstract] [Full Text] [Related]
16. Implications of the CMS final meaningful use information technology rule. Thompson T; Harolds JA Clin Nucl Med; 2010 Nov; 35(11):870-1. PubMed ID: 20940545 [TBL] [Abstract][Full Text] [Related]
17. Scientific uncertainty in regulating deliberate release of genetically engineered organisms: substantive judicial review and institutional alternatives. Deatherage SD HELR Harvard Environ Law Rev; 1987; 11(1):203-46. PubMed ID: 11650817 [No Abstract] [Full Text] [Related]